CTLA4 and esophageal squamous cell carcinoma: Several ongoing clinical trials (NCT03416244, NCT03377400, NCT02658214 and NCT03212469) are eagerly awaited to further clarify safety and efficacy of CTLA-4 inhibitors in immunotherapy of ESCC.